Mailankody, Sham

Publications

Sort by

Co-Author Network

selected publications

Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?. American journal of hematology. 2020 Letter GET IT
Times cited: 43
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 5
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 14
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 26
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer chemotherapy and pharmacology. 2017 Academic Article GET IT
Times cited: 1
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 2
The high price of anticancer drugs: origins, implications, barriers, solutions. Nature reviews. Clinical oncology. 2017 Review GET IT
Times cited: 230
Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & lymphoma. 2016 Letter GET IT
Times cited: 6
Controversies in multiple myeloma: Evidence-based update. Seminars in oncology. 2016 Review GET IT
Times cited: 5
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 8
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical biochemistry. 2016 Academic Article GET IT
Times cited: 41
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. Best practice & research. Clinical haematology. 2016 Review GET IT
Times cited: 4
An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials. JAMA oncology. 2016 Academic Article GET IT
Times cited: 49
Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. JAMA. 2016 Academic Article GET IT
Times cited: 24
Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. The oncologist. 2016 Academic Article GET IT
Times cited: 5
ASCO Plenary Sessions: impact, legacy, future. Seminars in oncology. 2016 Review GET IT
Times cited: 1
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. Mayo Clinic proceedings. 2016 Academic Article GET IT
Times cited: 18
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 20
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 Letter GET IT
Times cited: 12
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 12
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. Haematologica. 2015 Letter GET IT
Times cited: 19
Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. The oncologist. 2015 Academic Article GET IT
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA oncology. 2015 Academic Article GET IT
Times cited: 238
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015 Letter GET IT
Times cited: 14
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA oncology. 2015 Academic Article GET IT
Times cited: 80
Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature reviews. Clinical oncology. 2015 Review GET IT
Times cited: 88
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. Haematologica. 2014 Editorial Article GET IT
Times cited: 3
Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA otolaryngology-- head & neck surgery. 2014 Conference Paper GET IT
Times cited: 235
Dilemmas in treating smoldering multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Review GET IT
Times cited: 19
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. Clinical advances in hematology & oncology : H&O. 2014 Review GET IT
Times cited: 10
The road to treating smoldering multiple myeloma. Clinical lymphoma, myeloma & leukemia. 2014 Review GET IT
Times cited: 3
Comparative effectiveness questions in oncology. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 34
Minimal residual disease: what are the minimum requirements?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Letter GET IT
Times cited: 17
The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA. 2014 Academic Article GET IT
Times cited: 53
Smoldering multiple myeloma: present position and potential promises. European journal of haematology. 2013 Review GET IT
Times cited: 5
HIV, EBV, and monoclonal gammopathy. Blood. 2013 Comment GET IT
Times cited: 3
MGUS prevalence in a cohort of AML patients. Blood. 2013 Letter GET IT
Times cited: 3
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012 Review GET IT
Times cited: 91
Myeloma and second primary cancers. The New England journal of medicine. 2011 Letter GET IT
Times cited: 41
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011 Academic Article GET IT
Times cited: 152
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leukemia & lymphoma. 2010 Review GET IT
Times cited: 25
Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation. Transplantation. 2010 Academic Article GET IT
Times cited: 24

more ...

less ...

Background

education and training

M.B.,B.S., K S Hegde Medical Academy (Mangalore, India) 2008

Contact

full name

Sham Mailankody

VIVO Weill Cornell Medical College

Sham Mailankody Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name